Showing results (511-520 of 524) with videos related to
Sort By:
Pageof 53
Leukemia|July 21, 2006
International uniform response criteria for multiple myelomaB G M Durie, J-L Harousseau, J S Miguel, et al.Leukemia|July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)R Hájek, T Masszi, M T Petrucci, et al.Leukemia|November 21, 2008
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersA Dispenzieri, R Kyle, G Merlini, et al.Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2025
European Myeloma Network Group review and consensus statement on primary plasma cell leukemiaP Musto, M Engelhardt, N W C J van de Donk, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2016
Second primary malignancies in multiple myeloma: an overview and IMWG consensusP Musto, K C Anderson, M Attal, et al.Leukemia|December 21, 2007
Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaA Palumbo, S V Rajkumar, M A Dimopoulos, et al.Leukemia|June 5, 2009
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantationA Palumbo, O Sezer, R Kyle, et al.Leukemia|November 21, 2013
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)E M Ocio, P G Richardson, S V Rajkumar, et al.Leukemia|December 30, 2015
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working GroupJ Laubach, L Garderet, A Mahindra, et al.Pageof 53